Event JSON
{
"id": "df6d2e1632d3bb71edcbad4a01c25ff8eb6add40522f7b42865922904b6e6481",
"pubkey": "9c41d1165a76eda7abb3db9d665e67fdd23320dd1a8c6a65ff40a65935d667cc",
"created_at": 1738843341,
"kind": 1,
"tags": [
[
"r",
"https://www.cnbc.com/2025/02/06/bristol-myers-squibb-bmy-earnings-q4-2024.html"
],
[
"subject",
"Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance"
],
[
"published_at",
"1738843266"
],
[
"image",
"https://image.cnbcfm.com/api/v1/image/107405227-1713892869713-gettyimages-1880595297-BRISTOL_MYERS_SQUIBB.jpeg?v=1727437411\u0026w=1920\u0026h=1080"
],
[
"p",
"9c41d1165a76eda7abb3db9d665e67fdd23320dd1a8c6a65ff40a65935d667cc",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://image.cnbcfm.com/api/v1/image/107405227-1713892869713-gettyimages-1880595297-BRISTOL_MYERS_SQUIBB.jpeg?v=1727437411\u0026w=1920\u0026h=1080"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"Bristol Myers Squibb announced plans to cut $2 billion in costs by the end of 2027 to streamline operations and invest in new science and drug brands. The company is preparing for the loss of exclusivity on top-selling treatments, including Eliquis and Opdivo, and has reported fourth-quarter revenue and adjusted earnings that blew past expectations. The company's revenue guidance for 2025 fell short of Wall Street's expectations, but it still plans to cut $1.5 billion in costs by the end of 2025 and funnel that money into drug development."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqn3qaz9j6wmk602anmwwkvhn8lhfrxgxar2xx5e0lgzn9jdwkvlxqy56fv4\nhttps://image.cnbcfm.com/api/v1/image/107405227-1713892869713-gettyimages-1880595297-BRISTOL_MYERS_SQUIBB.jpeg?v=1727437411\u0026w=1920\u0026h=1080\nThe company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face competition from cheaper generics.\nhttps://www.cnbc.com/2025/02/06/bristol-myers-squibb-bmy-earnings-q4-2024.html",
"sig": "5233684519deeab376c98aacc92f1b3a89d55f3e7a7195b40bef69ac6269f91411c254afb8ef05bcfd4827208fb9ce8ca2032774bdda8ec1772594820a3e7164"
}
